Clinical Trials
We are developing a robust clinical trial program to test the efficacy and safety of our investigative medicines.
| Study | Trial Overview |
|---|---|
|
Program: JANX007 (PSMA x CD3 TRACTr)Status: Active, Recruiting |
The Phase 1 clinical trial (ENGAGER-PSMA-01) is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC. For additional information about the trial, please visit ClinicalTrials.gov using the identifier NCT05519449. |
|
Program: JANX014 (PSMA x CD3 TRACTr)Status: Active, Recruiting |
The Phase 1 clinical trial is a first-in-human, open-label, multicenter dose escalation trial to evaluate ascending doses of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). This trial will assess the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX014 as a single agent in adult subjects with mCRPC. For additional information about the trial, please visit ClinicalTrials.gov using the identifier NCT07545811. |
|
Program: JANX011 (CD19 ARM)Status: Active, Recruiting |
A Phase 1, first-in-human, open-label dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JANX011 in healthy adult volunteers. JANX011 is a CD19-targeted Adaptive Immune Response Modulator (ARM) being developed for autoimmune diseases. This study is intended to characterize key immune effects, including B-cell depletion, memory B-cell reset, T-cell expansion, and cytokine release syndrome (CRS) risk to inform subsequent clinical development in autoimmune indications. For additional information about the trial, please visit ClinicalTrials.gov using the identifier NCT07291323. |
|
Program: JANX013 (PSMA x CD28 TRACIr)Status: Active, Recruiting |
A Phase 1, first-in-human, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of JANX013 in combination with JANX007 in adult patients with mCRPC. The study is intended to evaluate biomarkers of immune activation, including T-cell expansion and persistence, to characterize the effects of tumor-restricted CD28 co-stimulation and inform future clinical development of JANX013. For additional information about the study, please visit ClinicalTrials.gov using the identifier NCT07813637. |